MedTrace Logo

A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

NCT03546894 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 111

Last updated 2024-07-15

No results posted yet for this study

Summary

The primary purpose of this study is to determine the differences in PFS for participants who have been receiving brigatinib as ALK inhibitor therapy for ALK+NSCLC compared to those participants receiving alectinib, ceritinib, lorlatinib, or other ALK inhibitors that may become available during study treatment.

Conditions

  • Anaplastic Lymphoma Kinase-positive
  • Carcinoma Non-small-cell Lung

Interventions

DRUG

Brigatinib

Brigatinib tablets.

DRUG

Alectinib

Alectinib capsules.

DRUG

Ceritinib

Ceritinib capsules.

DRUG

Lorlatinib

Lorlatinib capsules.

DRUG

Any FDA Approved ALK Inhibitors

FDA approved ALK inhibitors available for treatment.

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-23
Primary Completion
2023-02-13
Completion
2023-02-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03546894 on ClinicalTrials.gov